Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment

Publikation

Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment

Wissenschaftlicher Artikel/Review - 01.04.2007

Birchler Manfred T, Thuerl Christina, Schmid Daniel, Neri Dario, Waibel Robert, Schubiger August, Stöckli Sandro, Schmid Stephen, Goerres Gerrhard W

Zitation

Birchler M, Thuerl C, Schmid D, Neri D, Waibel R, Schubiger A, Stöckli S, Schmid S, Goerres G. Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2007; 136:543-8.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2007; 136

Veröffentlichungsdatum

01.04.2007

ISSN (Druck)

0194-5998

Seiten

543-8

Kurzbeschreibung/Zielsetzung

OBJECTIVE: In a phase I/II clinical study, we investigated tumor targeting in patients with head and neck squamous cell carcinomas (SCC), using an antibody directed against the extra-domain-B of fibronectin (EDB), a marker of angiogenesis and tissue remodeling. STUDY DESIGN AND SETTING: Five patients with SCC were injected with the 123-iodine-radiolabeled L19(scFv)2 antibody and underwent scintigraphic detection with single photon emission tomography with computerized tomography (SPECT/CT). In addition, 18F-fluorodeoxyglucose (18FDG) positron emission tomography with computerized tomography (PET/CT) was performed. RESULTS: Successful targeting of the primary tumor could be achieved in 4 of 5 patients and was comparable to PET imaging. No side effects were observed. CONCLUSIONS: Tumor targeting with the L19(scFv)2 antibody is also feasible for head and neck SCC. SIGNIFICANCE: These results may serve as a base for future therapeutical applications in human beings, with modified versions of the L19(scFv)2 antibody, designed to selectively deliver bioactive molecules into malignant tumors.